Description
Bortemib 2mg Injection is a targeted therapy used in the treatment of multiple myeloma, a type of blood cancer. The active ingredient, Bortezomib, is a proteasome inhibitor. It works by blocking the action of proteasomes, which are protein complexes within cells that break down unneeded or damaged proteins. By inhibiting proteasomes, Bortemib leads to an accumulation of these proteins within cancer cells, ultimately triggering their death. This mechanism is particularly effective against myeloma cells, which are sensitive to proteasome inhibition. Bortemib 2mg Injection is typically administered by a healthcare professional. The dosage and duration of treatment are determined by the patient’s specific condition and response to therapy. Common side effects may include fatigue, nausea, diarrhea, constipation, and peripheral neuropathy (nerve damage causing numbness or tingling). It is crucial to discuss any potential side effects with your doctor. Bortemib 2mg Injection should be stored at room temperature, protected from light, and kept out of reach of children. Always follow your doctor’s instructions regarding its use.
